Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia

Karen Yee,John M. Storring,Rena Buckstein,Richard A. Wells,Anargyros Xenocostas,Michael J. Kovacs,Kang Howson-Jan,Eunice S. Wang,Kristina Battista,Lisa Wang,Amit M. Oza,S. Percy Ivy,Andre C. Schuh

Sunitinib malate in patients with intermediate-2 or high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia

2014

Karen Yee
John M. Storring
Rena Buckstein
Richard A. Wells
Anargyros Xenocostas
Michael J. Kovacs
Kang Howson-Jan
Eunice S. Wang
Kristina Battista
Lisa Wang
Amit M. Oza
S. Percy Ivy
Andre C. Schuh

Myelodysplastic syndromes (MDS) are a heterogeneous group of malignant clonal disorders characterized by ineffective hematopoiesis and risk of progression to acute myeloid leukemia (AML) [1]. Recep...

Keywords:

Diabetes mellitus
Oncology
Chronic myelomonocytic leukemia
Sunitinib malate
Immunology
Medicine
Internal medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations